2020 Gastric Cancer Symposium (RP2002K)

February 22, 2020

Despite decreasing overall incidence of gastric cancer in the United States, the incidence of gastric cancer remains high and actually is increasing in certain populations. The heterogeneity of the disease makes management complex. We present a comprehensive multidisciplinary approach to the evaluation and management of gastric cancer that is tailor towards North Texas providers and the unique gastric cancer population that our region treats.

Target Audience

THIS ACTIVITY IS INTENDED FOR PROVIDERS IN THE SPECIALTIES OF: 

  • Surgery
  • Family Practice
  • Internal Medicine
  • Oncology (Medical)

Learning Objectives

  • Explain the heterogeneity associated with gastric cancer in terms of presentation, racial/ethnic differences, biologic subtypes, and treatment responsiveness.
  • Identify current approaches for early detection, screening, and modification or risk factors.
  • Describe current multidisciplinary approaches to the treatment of all stages of gastric cancer.
  • Identify various risk factors and pre-malignant conditions which can lead to gastric cancer, including their treatment.
  • Explain the role and limitations of various staging modalities for gastric cancer.
  • Describe current advancements in the multi-disciplinary treatment of gastric cancer.
Course summary
Available credit: 
  • 3.75 AMA
  • 3.75 Attendance
Course opens: 
01/23/2020
Course expires: 
02/21/2021
Event starts: 
02/22/2020 - 8:00am CST
Event ends: 
02/22/2020 - 1:30pm CST
Cost:
$0.00

Time

Topic

Presenter

8:00-8:30

Breakfast

 

Magnitude of the Problem and Diagnosis

  • Provide introduction, give background, common language to use
  • Highlight common risk factor (HP) and reflux as well as management strategies to deal with common and complex presentations
  • Focus on early lesions, role for surveillance and advanced techniques

8:30-8:45

Introduction / Welcome

Porembka

8:45-9:00

Risk factors: reflux, complex H. pylori, screening

Tavakoli

9:00-9:15

Early detection and treatment of precursor lesions

Suarez

9:15-9:35

Crossfire: Barretts, precursor lesion, advanced endoscopic management

(Moderator: Porembka, Panel: Hammer, Suarez, Tavakoli)

9:35-9:50

Q & A

 

9:50-10:10

Break – Coffee

 

State of the Art Treatment

  • Showcase UT’s strength in multidisciplinary treatment of gastric/GEJ tumors
  • Highlight MIS techniques / HIPEC / volume
  • Current clinical trial portfolio – immunotherapy

10:10-10:25

Advances in Surgical Management

Wang

10:25-10:40

Evolving role of radiation and new technologies

Aguilera

10:40-10:55

Rapid advances in systemic therapy: chemotherapy and immunotherapy

Kazmi

10:55-11:35

Crossfire: Resectable gastric cancer – highlight the staging considerations (CT, EUS, PET)

Perioperative therapy (FLOT)

Minimally invasive surgery (robot, etc)

(Moderator: Porembka; Panel: Wang, Kazmi, Aguilera, Sanjeevaiah)

11:35-11:50

Q & A

 

11:50-12:30

Break – Box Lunch

 

Crossfire

12:30-12:50

Crossfire: Peritoneal disease (need for staging laparoscopy), HIPEC (indications), Palliation (drains, stents, bypass, etc)

(Moderator: Porembka, Panel: Wang, Sanjeeviah/Kazmi, Suarez/Tavakoli, Hardi)

12:50-1:10

Crossfire: 35 year old with proximal gastric cancer 3 years out from surgery.

Management after a total gastrectomy, Surveillance (nutrition / cancer), Genetics, RD

(Moderator: Porembka; Panel: Wang, Sanjeevaiah/Kazmi, Suarez/Tavakoli, Hardi)

1:10-1:30

Q & A / Wrap Up

 

 

The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas Southwestern Medical Center designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 3.75 AMA
  • 3.75 Attendance

Price

Cost:
$0.00
Please login or create an account to take this course.